NasdaqGM:ESPR

Stock Analysis Report

Executive Summary

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).

Rewards

Revenue is forecast to grow 18.09% per year

Risk Analysis

Earnings are forecast to decline by an average of -6.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Flawless balance sheet with concerning outlook.

Share Price & News

How has Esperion Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ESPR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.8%

ESPR

0.8%

US Biotechs

1.3%

US Market


1 Year Return

7.0%

ESPR

16.4%

US Biotechs

19.4%

US Market

Return vs Industry: ESPR underperformed the US Biotechs industry which returned 16.4% over the past year.

Return vs Market: ESPR underperformed the US Market which returned 19.4% over the past year.


Shareholder returns

ESPRIndustryMarket
7 Day2.8%0.8%1.3%
30 Day26.6%8.9%2.6%
90 Day40.5%16.0%5.0%
1 Year7.0%7.0%17.4%16.4%22.0%19.4%
3 Year295.3%295.3%27.2%23.0%46.8%37.3%
5 Year34.1%34.1%4.6%-0.5%66.3%48.0%

Price Volatility Vs. Market

How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?

20.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ESPR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ESPR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ESPR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ESPR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ESPR is overvalued based on its PB Ratio (20.4x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-6.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ESPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ESPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ESPR's revenue (18.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ESPR's revenue (18.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Esperion Therapeutics performed over the past 5 years?

-25.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ESPR is currently unprofitable.

Growing Profit Margin: ESPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of -25.9% per year.

Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: ESPR has a negative Return on Equity (-139.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Esperion Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ESPR's short term assets ($253.5M) exceed its short term liabilities ($57.5M).

Long Term Liabilities: ESPR's short term assets ($253.5M) exceed its long term liabilities ($129.2M).


Debt to Equity History and Analysis

Debt Level: ESPR is debt free.

Reducing Debt: ESPR has no debt compared to 5 years ago when its debt to equity ratio was 9.6%.


Balance Sheet

Inventory Level: ESPR has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ESPR's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ESPR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ESPR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -0.3% each year


Next Steps

Dividend

What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ESPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Esperion Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Tim Mayleben (58yo)

7yrs

Tenure

US$9,724,839

Compensation

Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD9.72M) is above average for companies of similar size in the US market ($USD3.89M).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.7yrs

Average Tenure

53yo

Average Age

Experienced Management: ESPR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Age and Tenure

4.5yrs

Average Tenure

58yo

Average Age

Experienced Board: ESPR's board of directors are considered experienced (4.5 years average tenure).


Insider Trading

Insider Buying: ESPR insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$184,90008 Nov 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$36.98
BuyUS$2,797,56008 Nov 19
Bellevue Asset Management AG
EntityCompany
Shares75,000
Max PriceUS$37.30
BuyUS$259,10706 Sep 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares7,500
Max PriceUS$35.25
BuyUS$2,702,20806 Sep 19
Bellevue Asset Management AG
EntityCompany
Shares80,000
Max PriceUS$33.78
BuyUS$197,80002 Aug 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$39.56
BuyUS$2,132,56525 Jul 19
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$42.65
BuyUS$230,00001 Jul 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$46.00
BuyUS$200,00001 Apr 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$40.00
BuyUS$217,40021 Mar 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$43.48
SellUS$76,92521 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares1,700
Max PriceUS$45.25
SellUS$608,67121 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares13,629
Max PriceUS$44.66
BuyUS$2,494,35515 Mar 19
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$49.89
BuyUS$243,65014 Mar 19
Timothy Mayleben
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$48.73
BuyUS$3,303,25607 Jan 19
Bellevue Asset Management AG
EntityCompany
Shares80,000
Max PriceUS$41.29
BuyUS$1,995,72526 Dec 18
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$39.91
BuyUS$2,864,07019 Dec 18
Bellevue Asset Management AG
EntityCompany
Shares60,000
Max PriceUS$47.73

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Tim Mayleben (58yo)

    President

    • Tenure: 7yrs
    • Compensation: US$9.72m
  • Ken Fiorelli

    Senior Vice President of Technical Operations

    • Tenure: 0.3yrs
  • Keith Lenden (46yo)

    Vice President of Corporate Development & Strategy

    • Tenure: 0yrs
  • Bill Sasiela (53yo)

    Senior Vice President of Clinical Development

    • Tenure: 1.7yrs
  • Mark Glickman (53yo)

    Chief Commercial Officer

    • Tenure: 1.7yrs
    • Compensation: US$9.12m
  • Regina Cavaliere

    Chief Ethics & Compliance Officer

    • Tenure: 0.4yrs
  • Rick Bartram (37yo)

    CFO & Corporate Secretary

    • Tenure: 1.9yrs
    • Compensation: US$2.54m
  • Ashley Hall

    Chief Development Officer

    • Tenure: 1.7yrs
  • Alex Schwartz

    Senior Director of Investor Relations

    • Tenure: 1.6yrs
  • Renee Marotta

    Head of Marketing

    • Tenure: 0yrs

Board Members

  • Dan Janney (54yo)

    Independent Director

    • Tenure: 7.1yrs
    • Compensation: US$270.58k
  • Nicole Vitullo (62yo)

    Lead Independent Director

    • Tenure: 4yrs
    • Compensation: US$311.66k
  • Tim Mayleben (58yo)

    President

    • Tenure: 7yrs
    • Compensation: US$9.72m
  • Antonio Gotto (84yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$290.84k
  • Jay Shepard (61yo)

    Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$477.34k
  • Jeff Berkowitz (53yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$1.41m
  • Tracy Woody (49yo)

    Director

    • Tenure: 0.6yrs
  • Scott Braunstein (56yo)

    Independent Director

    • Tenure: 4.5yrs
    • Compensation: US$305.63k
  • Mark McGovern (66yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$287.35k

Company Information

Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Esperion Therapeutics, Inc.
  • Ticker: ESPR
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.403b
  • Shares outstanding: 27.33m
  • Website: https://www.esperion.com

Number of Employees


Location

  • Esperion Therapeutics, Inc.
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor
  • Michigan
  • 48108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ESPRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2013
0ETDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2013
0IIMLSE (London Stock Exchange)YesCommon StockGBUSDJun 2013

Biography

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). It ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 00:50
End of Day Share Price2019/12/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.